The End of “US First”: How Global Pricing Politics Is Rewriting Launch Strategy

For more than two decades, global pharmaceutical launch strategy followed a familiar pattern. The United States came first. Europe followed later, sometimes much later, after regulatory approval, health technology assessment, and national pricing negotiations had run their course.

The reasoning behind this sequencing rarely required explanation. The United States offered rapid revenue generation, relatively unconstrained pricing at launch, and a reimbursement system that generally followed market entry rather than preceding it. Europe, by contrast, required navigating a complex web of national health systems, payer negotiations, and formal value assessments before patients could access treatment.

Launching first in the United States therefore became the industry’s default approach. Europe was important, but it was slower, more fragmented, and often commercially constrained. That logic is beginning to unravel.

A convergence of pricing politics, regulatory reform, and early access mechanisms is reshaping how pharmaceutical companies think about global commercialisation. Launch sequencing once largely an operational decision tied to regulatory timelines is increasingly becoming a strategic lever capable of influencing pricing corridors, evidence generation, and long-term market access across multiple regions.

For companies approaching global launch, particularly emerging biotech organisations preparing their first commercial product, the order in which markets are entered may now materially affect the long-term economic value of the asset.

The historical logic of US-first launches

The US-first model developed in an era when pharmaceutical pricing and reimbursement systems operated largely independently. European countries relied heavily on international reference pricing, often benchmarking their prices against neighbouring markets. This created a strong incentive for manufacturers to carefully control the sequence in which lower-priced markets were entered.The United States, however, remained largely insulated from these dynamics. While European countries frequently referenced each other, US pricing was determined primarily by negotiations between manufacturers, pharmacy benefit managers, and insurers. International prices rarely played a meaningful role.This separation allowed companies to pursue a straightforward commercial strategy: establish a strong price in the United States, generate early revenue, and then gradually navigate European reimbursement processes without worrying that those decisions would influence US pricing.

In many cases, the model worked effectively. Oncology launches such as those involving checkpoint inhibitors followed precisely this trajectory, with US commercialisation preceding broad European reimbursement by one to two years.But several structural developments are now eroding the assumptions that supported that strategy.

Pricing politics has become a global variable

The first shift is political rather than regulatory. Drug pricing has become a central issue in US healthcare policy debates. Across multiple administrations and legislative proposals, policymakers have increasingly looked beyond the United States when discussing pharmaceutical costs.Proposals involving international price comparisons, sometimes referred to as “most favoured nation” style approaches, have periodically surfaced in policy discussions. Even when such proposals are not implemented directly, the political framing around them matters.The narrative has shifted from asking how drugs should be priced in the United States to asking why US patients pay more than patients elsewhere. That change in framing subtly alters the commercial landscape. European prices historically irrelevant to US pricing negotiations may increasingly influence political expectations and payer behaviour.For companies planning global launches, this introduces a new layer of strategic complexity. Pricing decisions made in one geography may now carry indirect consequences in another.

Europe itself is changing

At the same time, the European environment is becoming more coordinated. The EU Health Technology Assessment Regulation introduces Joint Clinical Assessments designed to harmonise how clinical evidence is evaluated across member states. While pricing and reimbursement decisions will remain national responsibilities, the clinical evidence underpinning those decisions will increasingly be shared.The implications are significant.

First, the evidence narrative surrounding a therapy may now spread across multiple European markets simultaneously rather than evolving independently in each country.

Second, early clinical positioning, particularly around comparator therapies and patient populations, may shape payer perceptions across the region more quickly than in the past.

This growing interconnectedness increases the importance of early strategic decisions.

A misaligned evidence package or poorly positioned clinical narrative may now influence multiple markets simultaneously.

Early access programmes are shaping the commercial narrative earlier

Alongside regulatory changes, early access mechanisms have quietly become one of the most influential components of European market entry.Compassionate use programmes, named patient supply, and national early access frameworks allow patients to receive treatment before formal reimbursement negotiations conclude. In rare diseases and specialised therapeutic areas, these pathways frequently represent the earliest opportunity for real-world clinical experience.Their importance extends well beyond patient access.

Early access programmes generate real-world evidence, shape physician familiarity with a therapy, and begin to define its place in treatment pathways. Clinicians develop expectations about which patients should receive the therapy, when it should be used, and how it compares with existing options. In other words, the commercial narrative begins forming before formal launch.

The experience of several advanced therapies illustrates this dynamic. Early access initiatives around gene therapies and CAR-T treatments in Europe generated critical real-world insights that later informed reimbursement discussions and payer confidence.

However, early access programmes can also create unintended consequences. Pricing assumptions, treatment sequencing patterns, or patient selection criteria established during early access may later constrain reimbursement negotiations.What begins as a humanitarian pathway can therefore become a structural determinant of commercial outcomes.

Launch sequencing has become a strategic discipline

These developments collectively create a new strategic dilemma.Companies preparing global launches must now evaluate a set of questions that were historically secondary considerations.Should Europe still follow the United States, or might early European access generate valuable evidence and clinical momentum? Could pricing decisions in one region create expectations or reference points elsewhere? Do early access programmes strengthen the long-term value proposition or risk establishing unsustainable treatment patterns? Answering these questions requires thinking about launch sequencing in a more structured way.

One useful way to conceptualise the challenge is through what might be called the Launch Sequencing Triangle.Three forces increasingly shape global launch decisions:Pricing Integrity, companies must maintain a price corridor that protects the long-term value of the asset across markets.Evidence Generation, real-world data and clinical experience are increasingly necessary to support payer confidence and treatment adoption.Revenue Timing, early revenue remains critical for many organisations, particularly emerging biotechs with limited commercial portfolios.Optimising across these three forces is rarely straightforward. Accelerating revenue may limit evidence generation. Generating extensive real-world data may require earlier access programmes that complicate pricing strategy.The challenge for leadership teams is to consciously balance these competing priorities rather than defaulting to historical launch patterns.

Several launch models operate

The first remains the traditional US first model, in which the United States is launched ahead of other markets. This approach remains appropriate in certain circumstances, particularly where early revenue generation is paramount or where European pricing risks are substantial.

The second model is parallel launch, where companies attempt to bring the United States and key European markets to patients within a relatively narrow timeframe. This requires earlier alignment of clinical evidence and payer engagement but can reduce the lag between regions.

The third model, still less common but increasingly discussed, is strategic Europe first positioning. In specific therapeutic areas, particularly rare diseases, early European access programmes may generate real-world evidence and clinician familiarity that strengthens the therapy’s global value proposition.

None of these models is inherently correct. What matters is that the choice is deliberate.

Strategic decisions must move earlier in development

Perhaps the most important implication of this shift is timing.Launch sequencing decisions cannot be made months before approval. By that stage, the underlying evidence base and clinical positioning of the therapy are largely fixed.Instead, these considerations must be integrated into development planning much earlier, often during late Phase II or early Phase III. At that stage, companies can still shape comparator selection, endpoint design, patient population definitions, and real-world evidence strategies. These decisions ultimately determine how the therapy will be evaluated by payers and clinicians across different health systems.The commercial implications of development choices are therefore becoming increasingly pronounced.

The risk of relying on outdated launch assumptions

Despite these changes, many organisations continue to follow launch planning templates built for a different commercial environment.Internal processes often assume that global commercial strategy begins shortly before regulatory approval. By that stage, however, many of the most consequential decisions have already been made.The danger of this inertia is rarely catastrophic. Most therapies will still reach patients eventually.The risk is more subtle: pricing corridors that are narrower than necessary, reimbursement negotiations that become unnecessarily prolonged, or missed opportunities to generate evidence that strengthens the therapy’s value propostion. In a healthcare environment where value demonstration is becoming increasingly central, those strategic details can materially influence long-term commercial performance.

A different way of thinking about launch order

For decades, the pharmaceutical industry has viewed launch sequencing primarily through the lens of operational feasibility, regulatory timelines, manufacturing readiness, and commercial infrastructure.That perspective is becoming incomplete. Global pricing debates, coordinated evidence assessments, and the growing influence of early access mechanisms mean that decisions in one geography can increasingly shape outcomes in another.What was once a series of largely independent regional launches is evolving into a more interconnected global strategy. For leadership teams navigating this environment, the question is no longer simply whether the United States should come first. The more relevant question may be whether treating launch sequencing as an operational afterthought risks undermining the global value proposition of the therapy itself.